Clinical Research Studies:
At Piedmont Eye Center we are dedicated to our patients and providing the latest technology available. To do our part to ensure technology continues to advance, we are enrolled in multiple clinical trials. If you would like more information about enrolling in one of our studies that apply to you, please contact our Research Coordinators, Jana King or Michelle Wells, at 434.947.3984 ext. 574. They will be happy to answer your questions.
Do you think you have conjunctivitis (pink eye)?
You and/or your child may be able to participate if you (or they):
- have had pink eye symptoms (e.g. redness, watering/discharge, or irritation) in at least one eye for no more than the past 3 days
- are interested in taking part in a research study for up to 13 days
- are willing to travel to the study center for appointments.
Qualified participants may receive the non-antibiotic investigational drug and study-related procedures and visits at no cost. Health insurance is not required to participate.
To find out more, and to see if you qualify, call us today.
(Study web posting, Version 1.0, 6 Jul 2017 [V01 USA])
Open Studies – Enrollment Open
Purpose: A phase 3 study to evaluate the efficacy and safety of bimatoprost sustained-release (SR) in patients with open-angle glaucoma or ocular hypertension. The study includes a 12-month treatment period with an 8-month extended follow-up.
Purpose: A Phase 3, Multi-center, Randomized, Double-Masked Study to Evaluate the Clinical Efficacy and Safety of SHP640 (PVP-Iodine 0.6% and Dexamethasone 0.1%) Ophthalmic Suspension Compared to Placebo in the Treatment of Adenoviral Conjunctivitis
Purpose: A Phase 3, Multi-center, Randomized, Double-Masked Study to Evaluate the Clinical Efficacy and Safety of SHP640 (PVP-Iodine 0.6% and Dexamethasone 0.1%) Ophthalmic Suspension Compared to Placebo in the Treatment of Bacterial Conjunctivitis
Open Studies- Closed Enrollment
Purpose: Safety and Efficacy of Abicipar Pegol (AGN-150998) in Patients With Neovascular Age-related Macular Degeneration